A Milestone for FSGS — And a Proud Moment for PARASOL

Published on April 14, 2026
A Milestone for FSGS — And a Proud Moment for PARASOL

Today marks a turning point for people living with focal segmental glomerulosclerosis (FSGS). More than a hundred years after the disease was first defined, the U.S. Food and Drug Administration (FDA) has granted its first ever approval of a drug for FSGS—an achievement that many in the glomerular disease community have been working toward for years.

Continue reading on website
Other news

Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design

April 7, 2026
AbstractIntroduction: Nephrotic syndrome (NS) clinical trials often rely on biomarkers or clinical measures as primary endpoints, but these may not fully capture the treatment benefits that matter most to patients. Edema-related swelling, a central manifestation of NS, profoundly affects patients’ health-related quality of life, including physical function, severe physical and mental symptoms, and

Board Review Bonus 5: Renal Amyloidosis

April 29, 2026
Episode 5: Board Review Bonus: Renal AmyloidosisIn this "Board Review Bonus" (BRB) episode, hosts Dr. Kenar Jhaveri and Dr. Koyal Jain provide a comprehensive clinical overview of amyloidosis—a complex and often enigmatic disease with significant renal implications. From the initial "mushy, smudgy" appearance on light microscopy to the precise measurements of electron microscopy, our hosts break d